Parallax Volatility Advisers
BOLD

Parallax Volatility Advisers’s Audentes Therapeutics, Inc BOLD Stock Holding History

Parallax Volatility Advisers’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,352
Closed -$74K – 5030
2017
Q4 		$74K Buy
+2,352
New +$64.6K ﹤0.01% 2986

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Parallax Volatility Advisers's BOLD Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2018, closing a stake of 2,352 shares — an estimated $74K sold.

Parallax Volatility Advisers first reported a position in BOLD in Q4 2017 and held it in 1 quarter. The position peaked at $74K in Q4 2017. 114 funds tracked by Wall St. Rank hold BOLD as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Audentes Therapeutics, Inc position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,352 Audentes Therapeutics, Inc shares in Q1 2018, an estimated $74K.
  • Parallax Volatility Advisers first reported a position in Audentes Therapeutics, Inc in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Audentes Therapeutics, Inc position peaked at $74K in Q4 2017.
  • 114 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.